WO2015183213A1 - Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid - Google Patents

Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid Download PDF

Info

Publication number
WO2015183213A1
WO2015183213A1 PCT/TR2014/000494 TR2014000494W WO2015183213A1 WO 2015183213 A1 WO2015183213 A1 WO 2015183213A1 TR 2014000494 W TR2014000494 W TR 2014000494W WO 2015183213 A1 WO2015183213 A1 WO 2015183213A1
Authority
WO
WIPO (PCT)
Prior art keywords
glutamic acid
amino
methyl
benzoyl
pteridinyl
Prior art date
Application number
PCT/TR2014/000494
Other languages
French (fr)
Inventor
Kader ÇÖMLEKÇİ
Fethi ŞAHİN
Bilgehan ABAY
Özlem YAZIR
Original Assignee
Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. filed Critical Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş.
Publication of WO2015183213A1 publication Critical patent/WO2015183213A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Definitions

  • the invention relates to solid,liquid,enteral and parenteral stable combinations of pharmaceutical forms comprising N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl)
  • API II N-[4-[[(2- Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) (hereafter refer to as API II) or pharmaceutically acceptable salts,particulary
  • API I
  • the formulation of the invention relates to a pharmaceutical dosage form and its combination which is not exist in Turkey and the world.
  • EP2046332 describes using 50 mg/ml methotrexate for the treatment of inflammatory autoimmune diseases.
  • EP2046813 describes protein binding methotrexate derivatives and pharmaceutical compositions comprising the methotrexate derivatives.
  • the formulation of the protein binding methotrexate derivative is intended to be used for the treatment of cancer and rheumatic disease.
  • the structural formula which mentioned in the independent claim will be explained in detail in the following;
  • the object of the invention is to provide the use of the most stable pharmaceutical dosage forms that containing API I and API II combination,indicating a long shelf life, used for preventive and therapeutic purpose,increasing patient compliance.
  • the invention relates to solid,liquid,enteral and parenteral stable combinations of pharmaceutical forms comprising N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl)
  • API I is an antineoplastic drug. However, it is used to treat many other diseases unrelated with cancer in lower doses. It is being used via intravenous and higher doses are being used to treat cancer.
  • API I is a cycle specific drug that is showing both antineoplastic and immunosuppressant activity .As an antimetabolite it inhibits dihydrofolate reductase enzyme which is responsible for reduction of API II to tetrahydro structure . Reduction of tetrahydro API II decreases the required level of one-carbon groups and accordingly, purines' ,DNA's and cellular protein synthesis is inhibited.
  • API I is being administered by orally and intravenously. It is well absorbed when given as a low single dose (below 50mg / ml). The absorption is irregular when given above this dosage and it is suitable administering in divided doses. It is completely absorbed when administered by intramuscular injection.
  • BP British Pharmacopoeia
  • USP American Pharmacopoeia
  • API II is a water soluble vitamin B-complex used for oral and parenteral administration. Deficiency can cause various hematological complications including megaloblastic anemia.
  • API II is a biochemically inactive compound that it is precursor of tetrahydrofolic acid and methyltetrahydrofolate. Tetrahydrofolic acid, methyltetrahydrofolate and other folic acid derivatives are necessary substances to sustain erythropoiesis normally. These substances are needed as cofactors for the synthesis of purine and thymidylate nucleic acid. API II and its derivatives are necessary for the conversion of amino acids to each other. API II is given by oral and parenteral administration. Peak levels have been seen within 1 hour.
  • API II is yellow to orange-brown coloured, odorless or very lightly scented crystalline powder.
  • BP British Pharmacopoeia
  • US Pharmacopeia US Pharmacopeia
  • it is very slightly soluble in water; insoluble in alcohol, acetone, chloroform and ether; rapidly soluble in dilute solutions of alkali hydroxides and carbonates; soluble in hydrochloric acid and sulfuric acid.
  • pH range of solution for injection is 8-1 1. It must be protected from light and avoided freezing.
  • Parenteral drugs are given to circulatory system directly or indirectly excepting gastrointestinal system with a syringe as a sterile single dose or multi-dose form of ready to use syringe or vial.
  • the pharmaceutical form is containing N- [4 - [[(2,4-Diamino-6- pteridinyl) methyl] methylamino] benzoyl] -L-glutamic acid (or N- [4 - ((2,4-Diaminopteri pyrimidin-6- ylmethyl) methylamino) benzoyl] -L (+) - glutamic acid) and N- [4 - [[(2- Amino-3,4-dihydro-4-oxo,-6-pteridinyl) methyl] methylamino] benzoyl] -L -glutamic acid (or N- (4- (2-Amino-4-hidroksipteridin-6-ylmethylamino) benzoyl)
  • Production of parenteral solution is comprising the production of small volume parenteral of different volumes of liquid dosage form.
  • Production of parenteral drug can be carried out in the fully automated production line named ready to use syringe filling line.
  • Parenteral solutions are filled into sterile pre-filled syringe, vial or PVC containers.They are administered by injection .
  • parenteral solutions may also be called injectable solutions.
  • injectable solutions must be sterile.
  • the pH of the solution must be equal or close to the pH of body fluids (7.4).
  • Osmolality of the solution must be isosmotic with body fluids or close to them.
  • lt must not contain pyrogen which has bacterial lipopolysaccharide structure and can cause fever (should be apyrogenic ).
  • the solution must not contain particulate matter (micro or macroparticle).
  • Parenteral treatment is administering therapeutic agents by other than gastrointestinal system.
  • fluid and electrolytes, vitamins, sugars, protein, blood or components, vaccines, several drugs for therapeutic or diagnostic purposes can be administered.
  • the pharmaceutical effect starts faster than oral route. Drugs which can not be absorbed easily and degraded in the digestive tract can be given in this way.
  • Parenteral administration is preferred when it is desired to act quickly, the patient can not take the drug orally
  • the way of administration is determined by the suitability of the vessel, the patient's choices and preferences of the physician.For instance; Although the irritant drugs administered intramuscularly, easily absorbable drugs such as insulin are given by subcutaneously. Effect starts quickly and continues during the desired time. Sterile preparations are produced in clean room conditions for helping to minimize the risk of pyrogenic and particulate matter. Quality assurance of these requirements in sterile manufacturing has great importance and this manufacturing process must be carried out according to the validated production methods and procedures.
  • the solution is prepared in class A environment which has a background of class B environment.
  • class A environment which has a background of class B environment.
  • parenteral drugs are manufactured generally in the form of ready to use syringes or vials in a single dose or rarely multidose, it can be mentioned two types of production process: Usually the issue depends on the education and behavior of the staff.
  • WFI water for injection
  • WFI 80-90% of water for injection is loaded into the reactor.
  • WFI is cooled gradually 50 ° C then 40 ° C. Cooling is performed by flowing WFI which is passing through opposite direction in the coil .
  • the solution is made isotonic or isohydric.Osmotic pressure of the solution is adjusted up to the pressure of body fluids.
  • the volume of solution (final volume in the recipe) is completed with water for injection.
  • Solution is stirred in accordance with the processes for production program. Dissolved oxygen in the solution is removed by sending nitrogen continuously during stirring.
  • the solution preparation process ends when dissolved oxygen completely removed by passing through nitrogen.
  • Solution is passed through firstly 0,45 ⁇ then 0.22 ⁇ membrane filter and samples are taken for analysis.lt is filtered in this way and samples are taken for the following in- process controls.
  • Sending the inert gas such as nitrogen continuously during the preparation process in the production tank is performed to provide removing oxygen and also mechanical stirring of the solution and mixing gas flow .Thus, a complete dissolution and homogeneity is obtained.
  • In-process controls are performed after preparation of the solution.
  • the solution is filtered 0.45 ⁇ and 0.22 ⁇ membrane filter with nitrogen respectively.
  • Filtered product is sent to filling line storage reactor. Preparation for filling and filling are performed after appropriate analysis results.
  • the present invention is formed based on these features of the formulation more detailed below.
  • Stable formulation for cancer and supportive care is established by using production methods mentioned above with API I and API II as active ingredients and the following excipients.
  • API I and API II forms because of their high solubility.
  • the ratio and the order of addition of buffering agents in the manufacturing process is determined to provide dissolving of the combination of the active ingredients.
  • Solubilizing and buffering agent in the pharmaceutical form sodium hydroxide is selected from sodium carbonate and derivatives.
  • Strong acid or alkali solutions cause damage in the area where they are injected.
  • Adjusting the pH is needed to increase the stability of the drug, prevent tissue pain, damage and irritation at the injection site, prevent the growth of microorganisms and increase physiological activity.
  • the reason of the pH changing is degradation of drug and substances that contaminated from glass or plastics containers and stoppers. Buffer solutions are used if the drug is degraded out of stable pH range.
  • buffering agent must be compatible with the drug.Injectable dosage form is desirable to adjust the pH using a suitable buffering agent. pH of the blood is between 7.3-7.5. The injected solution is at the same pH with plasma to prevent pain and irritation. Blood has a buffer capacity. pH adjusment may not be needed because of rapid dilution when intravenous solutions are injected very slowly
  • Priority is the stability of the preparation. This is why the pH of the solution is adjusted to 7.5 to 9.0 which the active agent is stable.
  • Chelating agent is added to protect patients from the toxicity of metal ions and make active ingredients stable. These stable combined pharmaceutical form can be applied parenterally, when we prefer to use a chelating agent; as edetic acid or edetate disodium hydrate, sodium, calcium disodium, dipotassium, cobalt, disodium, trisodium, disodium and derivatives .For any reason very low concentrations of heavy metals in the environment can accelerate oxidation. Therefore, chelating agents are being used to hold these substances. They generate stable water-soluble complexes.
  • a chelating agent as edetic acid or edetate disodium hydrate, sodium, calcium disodium, dipotassium, cobalt, disodium, trisodium, disodium and derivatives .
  • Isotonicity agent is added to the formula not to cause any damage to the patients' cells.
  • Isotonicity agent can be selected as sodium chloride,mannitol and- derivatives in this stable parenteral combined pharmaceutical form.
  • Isotonic solutions have equivalent pressure to the osmotic pressure of blood plasma. Hypotonic solution has lower osmotic pressure than the osmotic pressure of the blood plasma and the solution which has more osmotic pressure is called hypertonic solutions.
  • Sterile parenteral pharmaceutical preparation is equal to body pH (7.4) or close to it, preferably should be isotonic and pyrogen free.
  • the solution is desired to be isotonic to reduce the damage of the parenteral drug to the tissue and maintain the blood electrolyte balance.
  • Osmotic pressure of the solution (osmolality) is expressed in units of osmole / kg.
  • the solution which has lower osmotic pressure from body fluids or 0.9% NaCl is hypotonic. It causes hemolysis of erythrocytes.
  • the solution which has more osmotic pressure from body fluid is hypertonic and it causes constriction of erythrocytes. Any cosolvent or surfactan are not required because of the active substance is dissolved.
  • the solvent used during production in unit formula is water for injection and it is suitable for preparing parenteral solutions.
  • the raw material of the injection water is deionized water known as WPU.WPU is obtained by distillation by passing through the water heat exchanger at 96 ° C to 102 ° C. Pyrogenic substances substantially purified in this water.
  • the Water for Injection (WFI) obtained from the autoclave sterilization with contacting with water vapor.This sterilization is identified SIP (sterilization in place) and the process is carried out in situ sterilization.
  • Combined stable aqueous solution comprising API I and API II is filled into glass vials and use pre-filled syringe for parenteral use. Both filtration and terminal sterilization were administered. Parenteral solutions is maintained at 121 0 C for 15-20 minutes in autoclave sterilization.
  • Parenteral solutions must be sterile because of directly injected to people. Sterility is absence of living organisms such as bacteria and fungi which are reproduced in standard culture media.Sterilization is the destruction of these organisms.
  • Parenteral solutions are kept at 121 ° C during 15 to 20 minutes in autoclave sterilization.
  • Parenteral solution that unstable to the heat sterilization is filtered through membrane filters which is made of cellulose esters and derivatives and has undefined pore size . 0.22 ⁇ pore size filters are efficient for the removal of very small organisms.
  • Ready to use syringes are small primary packaging containers that made of glass, plastic, polymer or copolymer materials which drug or drug solvent is filled for parenteral purpose.Pre-filled syringe and vial containers should not contain any extractable substances that may change stability and increase toxicity of the product.
  • Stability is related to shelf life of the product. Time dependent changing of bacterial or chemical compound in the solution is undesired . Therefore stability enhancers and preservatives are added to the parenteral dosage forms.

Abstract

The invention is related to solid, liquid, enteral and parenteral stable combinations of pharmaceutical forms comprising N- [4 - [[(2,4-Diamino-6-pteridinyl) methyl] methylamino] benzoyl] -L-glutamic acid and N- [4 - [[(2- Amino-3,4-dihydro-4-oxo-6- pteridinyl) methyl] methylamino] benzoyl] -L- glutamic acid pharmaceutically acceptable salts, particulary monohydrate, sodium and disodium, as active ingredients.

Description

Pharmaceutical dosage forms containing N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid and N-[4-[[(2-Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid
Technical field
The invention relates to solid,liquid,enteral and parenteral stable combinations of pharmaceutical forms comprising N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl)
methylamino)benzoyl]-L(+)-glutamic acid ) (hereafter refer to as API I) and N-[4-[[(2- Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) (hereafter refer to as API II) or pharmaceutically acceptable salts,particulary
monohydrate,sodium and disodium, as active ingredients.
API I :
Figure imgf000002_0001
Figure imgf000003_0001
State of the Art
The formulation of the invention relates to a pharmaceutical dosage form and its combination which is not exist in Turkey and the world.
It is known that the formulation of 50 mg/ml methotrexate and protein binding methotrexate derivatives is used for the treatment of inflammatory autoimmune diseases,
EP2046332 describes using 50 mg/ml methotrexate for the treatment of inflammatory autoimmune diseases.
EP2046813 describes protein binding methotrexate derivatives and pharmaceutical compositions comprising the methotrexate derivatives. The formulation of the protein binding methotrexate derivative is intended to be used for the treatment of cancer and rheumatic disease.The structural formula which mentioned in the independent claim will be explained in detail in the following;
Figure imgf000003_0002
Technical problems that the invention aims to solve
The object of the invention is to provide the use of the most stable pharmaceutical dosage forms that containing API I and API II combination,indicating a long shelf life, used for preventive and therapeutic purpose,increasing patient compliance.
Description of the invention
The invention relates to solid,liquid,enteral and parenteral stable combinations of pharmaceutical forms comprising N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl)
methylamino)benzoyl]-L(+)-glutamic acid ) and N-[4-[[(2-Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) (hereafter refer to as API II) or pharmaceutically acceptable salt as active ingredient.
API I is an antineoplastic drug. However, it is used to treat many other diseases unrelated with cancer in lower doses. It is being used via intravenous and higher doses are being used to treat cancer.
API I is a cycle specific drug that is showing both antineoplastic and immunosuppressant activity .As an antimetabolite it inhibits dihydrofolate reductase enzyme which is responsible for reduction of API II to tetrahydro structure . Reduction of tetrahydro API II decreases the required level of one-carbon groups and accordingly, purines' ,DNA's and cellular protein synthesis is inhibited.
API I is being administered by orally and intravenously. It is well absorbed when given as a low single dose (below 50mg / ml). The absorption is irregular when given above this dosage and it is suitable administering in divided doses. It is completely absorbed when administered by intramuscular injection.
Regarding to API I, the British Pharmacopoeia (BP) is reported that the content is not less than %97 on dry basis and the American Pharmacopoeia (USP) reported that the content is not less than %98 on dry basis.lt is yellow to brown crystallized powder. Practically insoluble in water,chloroform and ether. It dissolves in dilute mineral acids and in dilute solutions of alkali hydroxides and carbonates. It must be protected from light.
API II is a water soluble vitamin B-complex used for oral and parenteral administration. Deficiency can cause various hematological complications including megaloblastic anemia.
API II is a biochemically inactive compound that it is precursor of tetrahydrofolic acid and methyltetrahydrofolate. Tetrahydrofolic acid, methyltetrahydrofolate and other folic acid derivatives are necessary substances to sustain erythropoiesis normally. These substances are needed as cofactors for the synthesis of purine and thymidylate nucleic acid. API II and its derivatives are necessary for the conversion of amino acids to each other. API II is given by oral and parenteral administration. Peak levels have been seen within 1 hour.
API II is yellow to orange-brown coloured, odorless or very lightly scented crystalline powder.According to British Pharmacopoeia (BP), practically it is insoluble in water and other organic solvents. According to US Pharmacopeia (USP), it is very slightly soluble in water; insoluble in alcohol, acetone, chloroform and ether; rapidly soluble in dilute solutions of alkali hydroxides and carbonates; soluble in hydrochloric acid and sulfuric acid. According to USP pH range of solution for injection is 8-1 1. It must be protected from light and avoided freezing.
Parenteral drugs are given to circulatory system directly or indirectly excepting gastrointestinal system with a syringe as a sterile single dose or multi-dose form of ready to use syringe or vial.The pharmaceutical form is containing N- [4 - [[(2,4-Diamino-6- pteridinyl) methyl] methylamino] benzoyl] -L-glutamic acid (or N- [4 - ((2,4-Diaminopteri pyrimidin-6- ylmethyl) methylamino) benzoyl] -L (+) - glutamic acid) and N- [4 - [[(2- Amino-3,4-dihydro-4-oxo,-6-pteridinyl) methyl] methylamino] benzoyl] -L -glutamic acid (or N- (4- (2-Amino-4-hidroksipteridin-6-ylmethylamino) benzoyl) -L (+) - glutamic acid) or their pharmaceutically acceptable salts, individually and / or in combination.
Production of parenteral solution is comprising the production of small volume parenteral of different volumes of liquid dosage form. Production of parenteral drug can be carried out in the fully automated production line named ready to use syringe filling line.
Parenteral solutions are filled into sterile pre-filled syringe, vial or PVC containers.They are administered by injection . Thus,parenteral solutions may also be called injectable solutions. Injectable solutions must be sterile.The pH of the solution must be equal or close to the pH of body fluids (7.4). Osmolality of the solution must be isosmotic with body fluids or close to them.lt must not contain pyrogen which has bacterial lipopolysaccharide structure and can cause fever (should be apyrogenic ). In addition, the solution must not contain particulate matter (micro or macroparticle).
Parenteral treatment is administering therapeutic agents by other than gastrointestinal system. In this way, fluid and electrolytes, vitamins, sugars, protein, blood or components, vaccines, several drugs for therapeutic or diagnostic purposes can be administered. The pharmaceutical effect starts faster than oral route. Drugs which can not be absorbed easily and degraded in the digestive tract can be given in this way.
There are many advantages of drug administered parenterally. Parenteral administration is preferred when it is desired to act quickly, the patient can not take the drug orally
(unconscious patients),the drug is destroyed by gastro-intestinal fluids and providing local effect and complete bioavailability.
The way of administration is determined by the suitability of the vessel, the patient's choices and preferences of the physician.For instance; Although the irritant drugs administered intramuscularly, easily absorbable drugs such as insulin are given by subcutaneously. Effect starts quickly and continues during the desired time. Sterile preparations are produced in clean room conditions for helping to minimize the risk of pyrogenic and particulate matter. Quality assurance of these requirements in sterile manufacturing has great importance and this manufacturing process must be carried out according to the validated production methods and procedures.
The solutions sterilized by filtration during the process are prepared in class C
environment. If sterile filtration is not possible,the solution is prepared in class A environment which has a background of class B environment.
Including small and large volume parenteral preparations, filling and other operations of aseptically prepared products are done in class A environment which has a background of class B environment.
Because of parenteral drugs are manufactured generally in the form of ready to use syringes or vials in a single dose or rarely multidose, it can be mentioned two types of production process: Mostly the issue depends on the education and behavior of the staff.
It is loaded to the production vessel according to process flow chart. Usually 85% of the volume of WFI (water for injection) is loaded into the reactor firstly. Then, active substance and excipients are loaded.
80-90% of water for injection is loaded into the reactor. Before loading into the production reactor, WFI is cooled gradually 50 ° C then 40 ° C. Cooling is performed by flowing WFI which is passing through opposite direction in the coil .
The solution is made isotonic or isohydric.Osmotic pressure of the solution is adjusted up to the pressure of body fluids.
The volume of solution (final volume in the recipe) is completed with water for injection.
Control and adjustment of pH is made.
Solution is stirred in accordance with the processes for production program. Dissolved oxygen in the solution is removed by sending nitrogen continuously during stirring.
The solution preparation process ends when dissolved oxygen completely removed by passing through nitrogen.
Solution is passed through firstly 0,45 μπι then 0.22 μπι membrane filter and samples are taken for analysis.lt is filtered in this way and samples are taken for the following in- process controls.
In-process controls;
a) pH
b) Viscosity
c) Particulate matter
d) Osmolality e) Clarity and homogeneity
Product is transferred to the reactor when in-process control results are in the
specifications.
Sending the inert gas such as nitrogen continuously during the preparation process in the production tank is performed to provide removing oxygen and also mechanical stirring of the solution and mixing gas flow .Thus, a complete dissolution and homogeneity is obtained.
In-process controls are performed after preparation of the solution. When in-process controls correspond to specifications,the solution is filtered 0.45 μιη and 0.22 μπι membrane filter with nitrogen respectively.
Filtered product is sent to filling line storage reactor. Preparation for filling and filling are performed after appropriate analysis results.
The present invention is formed based on these features of the formulation more detailed below.
Detailed description of the invention;
Stable formulation for cancer and supportive care is established by using production methods mentioned above with API I and API II as active ingredients and the following excipients.
Table 1
Figure imgf000007_0001
The development of the product had been done with using different base or salt of API I and API II. As a result, optimal form of API I and API II is found and it has been decided to use API I and API II forms because of their high solubility.
Also in the present invention the ratio and the order of addition of buffering agents in the manufacturing process is determined to provide dissolving of the combination of the active ingredients. Solubilizing and buffering agent in the pharmaceutical form; sodium hydroxide is selected from sodium carbonate and derivatives. Strong acid or alkali solutions cause damage in the area where they are injected. Adjusting the pH is needed to increase the stability of the drug, prevent tissue pain, damage and irritation at the injection site, prevent the growth of microorganisms and increase physiological activity. The reason of the pH changing is degradation of drug and substances that contaminated from glass or plastics containers and stoppers. Buffer solutions are used if the drug is degraded out of stable pH range. It should be considered that buffering agent must be compatible with the drug.Injectable dosage form is desirable to adjust the pH using a suitable buffering agent. pH of the blood is between 7.3-7.5. The injected solution is at the same pH with plasma to prevent pain and irritation. Blood has a buffer capacity. pH adjusment may not be needed because of rapid dilution when intravenous solutions are injected very slowly
Priority is the stability of the preparation. This is why the pH of the solution is adjusted to 7.5 to 9.0 which the active agent is stable.
Chelating agent is added to protect patients from the toxicity of metal ions and make active ingredients stable. These stable combined pharmaceutical form can be applied parenterally, when we prefer to use a chelating agent; as edetic acid or edetate disodium hydrate, sodium, calcium disodium, dipotassium, cobalt, disodium, trisodium, disodium and derivatives .For any reason very low concentrations of heavy metals in the environment can accelerate oxidation. Therefore, chelating agents are being used to hold these substances. They generate stable water-soluble complexes.
In the present invention,solution of the active ingredients combination was prepared.
Isotonicity agent is added to the formula not to cause any damage to the patients' cells. Isotonicity agent can be selected as sodium chloride,mannitol and- derivatives in this stable parenteral combined pharmaceutical form.Isotonic solutions have equivalent pressure to the osmotic pressure of blood plasma. Hypotonic solution has lower osmotic pressure than the osmotic pressure of the blood plasma and the solution which has more osmotic pressure is called hypertonic solutions.
Sterile parenteral pharmaceutical preparation is equal to body pH (7.4) or close to it, preferably should be isotonic and pyrogen free. The solution is desired to be isotonic to reduce the damage of the parenteral drug to the tissue and maintain the blood electrolyte balance. Osmotic pressure of the solution (osmolality) is expressed in units of osmole / kg.
The solution which has lower osmotic pressure from body fluids or 0.9% NaCl is hypotonic. It causes hemolysis of erythrocytes. The solution which has more osmotic pressure from body fluid is hypertonic and it causes constriction of erythrocytes. Any cosolvent or surfactan are not required because of the active substance is dissolved.
There is no need to use any microbial preservative such as benzyl alcohol because aqueous solution which is containing API I and API II is stable during shelf life.
The solvent used during production in unit formula is water for injection and it is suitable for preparing parenteral solutions. The raw material of the injection water is deionized water known as WPU.WPU is obtained by distillation by passing through the water heat exchanger at 96 ° C to 102 ° C. Pyrogenic substances substantially purified in this water. The Water for Injection (WFI) obtained from the autoclave sterilization with contacting with water vapor.This sterilization is identified SIP (sterilization in place) and the process is carried out in situ sterilization.
Combined stable aqueous solution comprising API I and API II is filled into glass vials and use pre-filled syringe for parenteral use. Both filtration and terminal sterilization were administered. Parenteral solutions is maintained at 121 0 C for 15-20 minutes in autoclave sterilization.
Parenteral solutions that sensitive to heat is sterilized by filtration with defined pore size of membrane filter made of cellulose ester. 0.22 um pore size filters are efficient for removing very small organisms. But the solutions that filled in the ready for use syringe filling line is subjected to sterilization at 121 ° C for 20 minutes like ampoules. After the sterilization process samples are sent to the microbiology.
Parenteral solutions must be sterile because of directly injected to people. Sterility is absence of living organisms such as bacteria and fungi which are reproduced in standard culture media.Sterilization is the destruction of these organisms.
Parenteral solutions are kept at 121 ° C during 15 to 20 minutes in autoclave sterilization. Parenteral solution that unstable to the heat sterilization is filtered through membrane filters which is made of cellulose esters and derivatives and has undefined pore size . 0.22 μπι pore size filters are efficient for the removal of very small organisms.
Ready to use syringes are small primary packaging containers that made of glass, plastic, polymer or copolymer materials which drug or drug solvent is filled for parenteral purpose.Pre-filled syringe and vial containers should not contain any extractable substances that may change stability and increase toxicity of the product.
Stability is related to shelf life of the product. Time dependent changing of bacterial or chemical compound in the solution is undesired . Therefore stability enhancers and preservatives are added to the parenteral dosage forms.
We can provide stable formulation comprising API I and API II together.Also it is possible to market the product separately.

Claims

1. Stable combined pharmaceutical forms comprising as active compounds N-[4-
[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid ) and N-[4-[[(2-Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) or pharmaceutically acceptable salts thereof which use of solid and liquid, enteral and parenteral
2. Use of according to claim 1, as an active compound N-[4-[[(2,4-Diamino-6- pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid ) and pharmaceutically acceptable salts thereof, particularly monohydrate, sodium and disodium salts
3. Use of according to claim 2, as active compound N-[4-[[(2-Amino-3,4- dihydro -4- oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-
Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) and their pharmaceutically acceptable salts thereof, in particular monohydrate, sodium and disodium salts 4. According to claim 3, as active compound N-[4-[[(2,4-Diamino-6- pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid ) and N-[4-[[(2- Amino-3,
4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L- glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)- L(+)-glutamic acid) or pharmaceutically acceptable salts thereof, single and/or combined comprising as pharmaceutical dosage forms
5. Use of according to claim 4, as active compound N-[4-[[(2,4-Diamino-6- pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid ) and N-[4-[[(2-
Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L- glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)- L(+)-glutamic acid) or pharmaceutically acceptable salts, use of N-[4-[[(2,4- Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4- ((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid )
10 mg/ml-50 mg/ml dosage and use of N-[4-[[(2-Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl] -L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) 0, 1 mg/ml - 5 mg/ml dosage
6. According to claim 1, as active compound comprising N-[4-[[(2,4-Diamino-6- pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid ) and N-[4-[[(2- Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L- glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)- L(+)-glutamic acid) or pharmaceutically acceptable salts stable combined pharmaceutical forms which applied parenteral
7. According to claim 6, pharmaceutically acceptable salts stable combined
pharmaceutical forms which applied parenteral, use of chelators as edetic acid or edetate disodium hydrate, sodium, calcium disodium, dipotassium, cobalt, disodium, trisodium, magnesium disodium and their derivatives
8. Chelating agent according to claim 7, use of edetate disodium dihydrate in
particular in the range of %0,005-2 mg/ml
9. According to claim 6, pharmaceutically acceptable salts stable combined
pharmaceutical forms which applied parenteral, use of isotonic agent as sodium chloride, mannitol and derivatives 10. According to claim 9, use of isotonic agent as %0, 1 - 0,9 mg/ml of sodium chloride in particular
11. According to claim 6, pharmaceutically acceptable salts stable combined
pharmaceutical forms which applied parenteral, use of solubilizing and buffering agent as sodium hydroxide, sodium carbonate and their derivatives
12. Solubilizing and buffering agent according to claim 1 1, the use of sodium
hydroxide in particular as solid and solution in the range of % 0, 1-20 mg/ml 13. Use of stable combined pharmaceutical forms according to claim 1, comprising protective agents excluding the use benzyl alcohol due to 'Gasping Syndrome' which leads to death
14. Stable combined pharmaceutical forms according to claim 1, packaged with pre- filled syringe or vial of glass and plastic
15. Stable combined pharmaceutical forms according to claim 1, sterilized by autoclave or filtration 16. Stable combined pharmaceutical forms according to claim 1, put on market as combo-pack (two different pharmaceutical forms presented with one secondary packaging)
PCT/TR2014/000494 2014-05-28 2014-12-09 Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid WO2015183213A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201405970 2014-05-28
TR2014/05970 2014-05-28

Publications (1)

Publication Number Publication Date
WO2015183213A1 true WO2015183213A1 (en) 2015-12-03

Family

ID=52596587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2014/000494 WO2015183213A1 (en) 2014-05-28 2014-12-09 Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid

Country Status (1)

Country Link
WO (1) WO2015183213A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046813A2 (en) 2006-07-28 2009-04-15 medac Gesellschaft für klinische Spezialgeräte mbH Protein-binding methotrexate derivatives, and medicaments containing the same
EP2046332A2 (en) 2006-07-21 2009-04-15 medac Gesellschaft für klinische Spezialgeräte mbH Concentrated methotrexate solutions
US20110280932A1 (en) * 2010-05-13 2011-11-17 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046332A2 (en) 2006-07-21 2009-04-15 medac Gesellschaft für klinische Spezialgeräte mbH Concentrated methotrexate solutions
EP2046813A2 (en) 2006-07-28 2009-04-15 medac Gesellschaft für klinische Spezialgeräte mbH Protein-binding methotrexate derivatives, and medicaments containing the same
US20110280932A1 (en) * 2010-05-13 2011-11-17 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DULAL C. CHATTERJI ET AL: "Thermal and photolytic decomposition of methotrexate in aqueous solutions", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 67, no. 4, 1 April 1978 (1978-04-01), pages 526 - 531, XP055180778, ISSN: 0022-3549, DOI: 10.1002/jps.2600670422 *
HIGNITE C E ET AL: "SEPARATION AND IDENTIFICATION OF IMPURITIES IN PARENTERAL METHOTREXATE DOSAGE FORMS", CANCER TREATMENT REPORTS, vol. 62, no. 1, 1978, pages 13 - 18, XP008175793, ISSN: 0361-5960 *
JOSEPH F. GALLELLI ET AL: "Assay of methotrexate in the presence of its decomposition products and other folic acid analogs", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 56, no. 3, 1 March 1967 (1967-03-01), pages 387 - 389, XP055180854, ISSN: 0022-3549, DOI: 10.1002/jps.2600560317 *
VINCKE B J ET AL: "Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 54, no. 3, 15 September 1989 (1989-09-15), pages 181 - 189, XP023736092, ISSN: 0378-5173, [retrieved on 19890915], DOI: 10.1016/0378-5173(89)90095-1 *

Similar Documents

Publication Publication Date Title
JP5522877B2 (en) Moxifloxacin / sodium chloride preparation
EP1948133B1 (en) Argatroban formulation comprising an acid as solubilizer
US9572887B2 (en) Formulations of bendamustine
JP7178731B2 (en) Solid pharmaceutical compositions containing biopterin derivatives and uses of such compositions
JP6892494B2 (en) Aqueous formulation containing paracetamol and ibuprofen
TWI544934B (en) Improved pharmaceutical compositions containing a fluoroquinolone antibiotic drug
KR101843613B1 (en) Pharmaceutical pemetrexed solution
JP2017514924A (en) Preparation of cyclophosphamide liquid concentrate
EP2666463A1 (en) Stabilized liquid composition comprising pemetrexed
KR20180066239A (en) An aqueous composition comprising dantrolene
JP2020125359A (en) Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof
CN110464846B (en) Meloxicam composition, preparation method and application thereof
WO2015183213A1 (en) Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid
WO2014083071A1 (en) Injectable liquid formulation of the combination of tramadol and paracetamol
WO2014007239A1 (en) Composition containing amphotericin b
JP2000219628A (en) Previously mixed injectable composition of alatrofloxacin
WO2016071784A1 (en) Compositions comprising finafloxacin and tris
WO2023183055A1 (en) Ready-to-administer hydromorphone formulations
RU2545903C1 (en) Pharmaceutical composition in form of lyophilisate for preparation of solution for parenteral application and method of obtaining thereof
EP2934524B1 (en) Penethamate veterinary injectable formulations
WO2020077564A1 (en) Teniposide injection solution having good dilution stability and preparation method therefor
EP2976063A1 (en) Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof
US20130096163A1 (en) Injectable dosage form of flupirtine
WO2000067753A1 (en) Parenteral formulation of 5-(2-chloroethyl)-4-methylthiazole edisylate(clomethiazole edisylate)
WO2011101865A2 (en) Stable pharmaceutical compositions of clopidogrel for parenteral delivery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14841373

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14841373

Country of ref document: EP

Kind code of ref document: A1